Allergy Therapeutics PLC (LON:AGY) has initiated a peanut allergy biomarker study that will support the clinical programme for a phase I trial later this year of its potentially breakthrough short-course vaccine candidate.
Researchers from Imperial College London have begun work on blood samples from peanut allergy patients to evaluate the group’s virus-like particle inoculation.
Specifically, the scientists will seek to confirm its hypoallergic potential and its “potent immune response”.
The results will then support the already-strong preclinical research package that has provided proof-of-concept for sustained immunity and protection against peanut anaphylaxis after a single vaccination, the drug group said.
Current treatments such as desensitisation or patches can take several years to work.
Allergy Therapeutics’ approach is designed to require just three injections to induce sustained protection.
“A safe and effective short-course peanut allergy vaccine would be a significant breakthrough product, offering life-changing benefits to sufferers affected by this condition,” said Allergy’s chief executive Manuel Llobet in a statement.
“The data we have generated so far for our peanut vaccine candidate give us confidence in its potential and through this study we have an opportunity to build on that confidence and provide our upcoming phase I study with the greatest chances of success.”
The company pointed out that its short-course vaccine candidate represented a “significant differentiated opportunity” in the US$8bn food allergy market.